Aclarion, Inc. (Nasdaq: ACON, ACONW), a healthcare technology company using biomarkers and augmented intelligence to identify the source of chronic low back pain, has announced the addition of Lanman Spinal Neurosurgery as a clinical site in its CLARITY trial. The private practice, based in Beverly Hills, is recognized for its expertise in complex spinal procedures and high surgical volume. This marks the first private practice site in the trial, reflecting growing interest in integrating Nociscan into real-world clinical workflows beyond academic medical centers.
Dr. Todd Lanman, a neurosurgeon with over 25 years of experience and founder of Lanman Spinal Neurosurgery, emphasized the importance of precise diagnostics. “Nociscan introduces a new layer of clarity by leveraging MR Spectroscopy to identify pain-generating discs in ways that standard MRI cannot,” he said. “The CLARITY trial is particularly important because it is designed to evaluate how this technology can enhance clinical decision-making. This ability to match the right procedure to the right patient is what moves the field forward.”
The CLARITY trial is a prospective, randomized, multi-center study involving 300 patients evaluating Nociscan in those undergoing surgical treatment (fusion or total disc replacement) for discogenic low back pain. The primary endpoint is change in back pain measured on a 100mm VAS at 12 months compared to baseline, with several secondary endpoints. Aclarion expects an initial internal data readout and public disclosure of early interim results in Q4 2026.
Ryan Bond, Chief Strategy Officer of Aclarion, highlighted the significance of this addition. “Private practice spine surgeons play a critical role in treating the majority of patients suffering from chronic low back pain, and the inclusion of Lanman Spinal Neurosurgery reflects the growing demand for more precise, data-driven tools in everyday clinical practice,” he said. “Dr. Lanman is widely recognized for his commitment to innovation and patient-centered care, and we are excited to partner with his team as we continue to expand CLARITY.”
Chronic low back pain affects approximately 266 million people worldwide. Aclarion’s Nociscan is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. It quantifies chemical biomarkers associated with disc pain, providing critical insights that can optimize treatment strategies. When all Nociscan-positive discs are treated, the technology demonstrates a 97% surgical success rate.
For more information about CLARITY, visit CLARITY Trial. To find a Nociscan center, view the site map here.
